2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14164R
    Zileuton (Standard) 111406-87-2
    Zileuton (Standard) is the analytical standard of Zileuton. This product is intended for research and analytical applications. Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.
    Zileuton (Standard)
  • HY-14164S
    Zileuton-d4 1189878-76-9 98%
    Zileuton-d4 is the deuterium labeled Zileuton. Zileuton (A 64077) is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.
    Zileuton-d4
  • HY-14165A
    (S)-Veliflapon 128253-32-7 99.44%
    (S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood.
    (S)-Veliflapon
  • HY-141712
    ZA18 2696407-32-4 98%
    ZA18 is a selective TRPM2 channel inhibitor, with an IC50 value of 6.2 μM. ZA18 can effectively suppress intracellular Ca2+ overload triggered by TRPM2 channel activation. ZA18 significantly reduce the mortality of SH-SY5Y cells induced by H2O2. ZA18 can be used for the study of ischemia-reperfusion injury, inflammation, or other neurodegenerative diseases.
    ZA18
  • HY-141713
    ZA10 98%
    ZA10 is a selective TRPM2 channel inhibitor, with an IC50 value of 8.1 μM. ZA10 can effectively suppress intracellular Ca2+ overload triggered by TRPM2 channel activation. ZA10 significantly reduce the mortality of SH-SY5Y cells induced by H2O2. ZA10 can be used for the study of ischemia-reperfusion injury, inflammation, or other neurodegenerative diseases.
    ZA10
  • HY-141843
    BRD4-IN-2 2679925-55-2 98%
    BRD4-IN-2 is a bromodomain BRD4 inhibitor with an IC50 value of 9.9 nM.
    BRD4-IN-2
  • HY-141864
    ITK/TRKA-IN-1 2655557-54-1 98%
    ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC50 value of 1.0 nM and 96 % inhibition, respectively.
    ITK/TRKA-IN-1
  • HY-142032
    RBM10-8 2407372-42-1 98%
    RBM10-8 is irreversible inhibitor of recombinant  human sphingosine-1-phosphate lyase (hS1PL) . Sphingosine-1-phosphate (S1P) is a sphingolipid (SL) that acts as a signaling molecule regulating diverse cellular processes such as cell proliferation and differentiation, angiogenesis, immune function, inflammation, and development.
    RBM10-8
  • HY-142100
    Licoagrochalcone C 325144-68-1
    Licoagrochalcone C, a flavonoid, reveals efficacious inhibitory activity on NF-κB transcription. Licoagrochalcone C shows significant inhibitory activity on LPS (HY-D1056)-induced NO production.
    Licoagrochalcone C
  • HY-142123
    Fluocortolone 152-97-6 98%
    Fluocortolone is an orally active anti-inflammatory agent that effectively reduces plasma fibrinogen levels. Fluocortolone inhibits Mycobacterium butyricum-induced foot edema in a rat model of adjuvanted joint inflammation (3-12 mg/kg).
    Fluocortolone
  • HY-142644
    ATX inhibitor 7 1646784-47-5 98%
    ATX inhibitor 7 is a autotaxin inhibitor and shows good oral exposure.
    ATX inhibitor 7
  • HY-142676
    PI3K-IN-26 1918151-65-1 98%
    PI3K-IN-26 is a potent PI3K inhibitor with an IC50 of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1).
    PI3K-IN-26
  • HY-142677
    PI3K-IN-27 2742654-38-0 98%
    PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1).
    PI3K-IN-27
  • HY-142686
    SGK1-IN-3 2891696-18-5 98%
    SGK1-IN-3 (compound 3a) is a potent SGK1 inhibitor with an IC50 of <1 μM. SGK1-IN-3 has the potential for the research of osteoarthritis.
    SGK1-IN-3
  • HY-142703
    RORγt inverse agonist 28 2741870-21-1 98%
    RORγt inverse agonist 28 is a potent reverse agonist of RORγt. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 28 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 6) .
    RORγt inverse agonist 28
  • HY-142834
    RORγt/DHODH-IN-2 2641758-86-1 98%
    RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research.
    RORγt/DHODH-IN-2
  • HY-142843
    RORγt/DHODH-IN-1 2764662-15-7 98%
    RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual RORγt/DHODH inhibitor, with IC50s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity.
    RORγt/DHODH-IN-1
  • HY-142847
    RORγt/DHODH-IN-3 2764662-16-8 98%
    RORγt/DHODH-IN-3 (compound (S)-14d) is a dual RORγt/DHODH inhibitor, with IC50s of 0.098 μM and 0.432 μM, respectively. RORγt/DHODH-IN-3 exhibits remarkable in vivo anti-inflammatory activity.
    RORγt/DHODH-IN-3
  • HY-142920
    LMP7-IN-1 2671040-07-4 98%
    LMP7-IN-1, a Boronic acid derivative, is a potent and selective immunoproteasome subunit LMP7 (β5i) inhibitor with an IC50 of 1.83 nM (WO2021143923A1; compound 20).
    LMP7-IN-1
  • HY-142932
    BTK-IN-6 2662512-08-3 98%
    BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8).
    BTK-IN-6
Cat. No. Product Name / Synonyms Application Reactivity